Alida Biosciences Inc.

Alida Biosciences Inc. has raised $7.5M in total funding. The most recent round was Series A.

Alida Biosciences Inc. is headquartered in San Diego, CA.

EpiPlex™ assay detects RNA modifications by proximity barcoding and short read RNA sequencing, revealing insights into gene regulation for disease research.

Standard RNA-seq misses RNA modifications like m6A, inosine, and pseudouridine, and existing methods for detecting them are cumbersome, slow, and struggle with limited or difficult sample types.

AlidaBio offers the EpiPlex platform as turnkey profiling services or in-lab kits that detect multiple RNA modifications alongside gene expression in one workflow, with EpiScout software to analyze the results.

Uses proximity barcoding and engineered binders to detect multiple RNA modifications (m6A, inosine, pseudouridine) simultaneously in a single assay, with spike-in normalization and validated performance on hard samples like FFPE and liquid biopsy.

Alida Biosciences, co-founded by CEO Gudrun Stengel and Byron Purse, raised a Series A (bringing total funding to about $12.6M) led by Genoa Ventures with FusionX Ventures and Vertical Venture Partners, plus NIH SBIR grant support.